NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Hindustan Unilever Ltd Reports 20.9 Percent Year-on-Year Rise in Consolidated Net Profit

Hindustan Unilever Ltd (HUL) has reported a 20.9 percent year-on-year rise in consolidated net profit attributable to owners of the company at Rs 2,992 crore for the fiscal fourth quarter. This significant increase is compared to Rs 2,464 crore in the year-ago period, according to the company's exchange filing. The reported profit includes gains from divestment in Nutritionalab Pvt Ltd.

The FMCG major's consolidated revenue from continuing operations rose 7.6 percent to Rs 16,351 crore from Rs 15,190 crore in the corresponding quarter last year. The numbers relate to HUL's continuing operations. Additionally, EBITDA from continuing operations grew 6 percent year-on-year to Rs 3,841 crore, compared with Rs 3,619 crore a year earlier. The EBITDA margin narrowed to 23.5 percent from 23.8 percent in the year-ago quarter.

HUL reported volume growth of 6 percent for the quarter, ahead of the CNBC-TV18 poll estimate of 4-5 percent. The company's board approved a final dividend of Rs 22 per share for FY26. HUL had earlier paid an interim dividend of Rs 19 per share, taking the total dividend for the year to Rs 41 per share.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

On a standalone basis, HUL reported revenue from continuing operations of Rs 15,733 crore, while net profit attributable to the company stood at Rs 2,930 crore for the March quarter. The company said profit growth during the quarter was supported by steady operating performance as well as gains linked to portfolio actions, including the divestment of stake in Nutritionalab Pvt Ltd.

Segment Results Comparison

SegmentSales Growth (Q4 FY26)Sales Growth (Q4 FY25)
Homecare9%-
Beauty & Wellbeing8%-
Personal Care5%-
Foods5%-

The largest business segment, Homecare, posted 9 percent sales growth in the quarter, its highest growth in 11 quarters, the company said in a media statement. HUL attributed strong performance from fabric wash, household care, and liquids portfolio. The segment's consolidated revenue was reported at Rs 6,344 crore.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Beauty & Wellbeing posted an 8 percent underlying sales growth (USG), driven by standout performance in hair care, HUL said, reporting revenue of Rs 3,697 crore, up from Rs 3,265 crore reported in the same quarter last year.

Personal Care grew USG by 5 percent in the quarter ended March 31, powered by strong performance in the skin cleansing segment, HUL said. The segment was driven by outperformance in marquee brands Dove and Lux. However, oral care reported low-single digit growth while Closeup strengthened its market share.

Under foods, USG rose 5 percent, with revenue rising to Rs 3,566 crore from Rs 3,416 crore. Tea reported low-single digit UVG. Coffee continued its strong double-digit growth momentum supported by volume and price, the FMCG major added.

For the full year, turnover was pegged at Rs 63,763 crores, driven by 4 percent underlying volume growth (UVG). "Financial Year 2026 witnessed an improved demand environment driven by supportive macro-economic policies. During the year, we took decisive actions to accelerate growth, including sharpening our portfolio, scaling investments to create desire at scale, strengthening frontline demand generation capabilities, and simplifying the organisation to drive speed, focus, and execution," HUL's CEO and Managing Director Priya Nair added.

Investor Takeaway

Investors should note Hindustan Unilever's revenue growth and net profit increase in Q4.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.